National Pharmaceutical Council

Today, the Institute for Clinical and Economic Review (ICER) released its fourth annual Fair Access report, which values the alignment of select prescription drug coverage policies with a small subset of “Fair Access” criteria that ICER developed in 2020.   Though the report has limitations, it highlights a persistent challenge in the U.S. healthcare system: patients continue to face unnecessary and harmful barriers to care due to poorly designed health benefits.     Read our full response to this year’s report below.

Today in NPC This Week: What will PBM reform look like, 340B in the states, the IRA’s impact on postapproval research, NPC’s 2025 board leadership, and more   ☃️ NPC This Week will pause over the holidays. Look for us again in your inbox on Tuesday, January 7, 2025. Happy holidays from the NPC team! Want to get NPC This Week in your inbox? Subscribe here: https://lnkd.in/ekY9Dxzr

🤔 💊 Should drug prices be regulated in the United States?    Thank you to Roxanne E. Nelson, for the invitation to contribute to her newest report “U.S. Drug Pricing” in CQ Press. I appreciate the opportunity to share National Pharmaceutical Council's research on why U.S. drug prices should not be regulated. Government price regulations, like those introduced by the Inflation Reduction Act, can have unintended consequences like reduced patient access and fewer new treatment options for diseases. Learn more about this crucial policy conversation in CQ Researcher: https://lnkd.in/gEbBfYKu

ICER’s UPI reports do more harm than good: They have serious methodological limitations, contradict ICER’s core value assessment framework, and ignore a tremendous amount of evidence submitted by manufacturers.  One critical limitation is ICER’s failure to adjust for inflation when calculating the headline number in the report. If ICER simply followed this best practice for economic analysis and inflation-adjusted their findings using CPI-U, the estimated $815 million “increase” in this year’s report disappears, becoming instead a $10 million decrease, causing the premise of the entire report to collapse. Read more below:

AstraZeneca’s Bruce Wilson has been elected to continue his work on the National Pharmaceutical Council’s Board of Directors, serving as Treasurer and Chair of the Audit and Budget Committee. Learn more about NPC’s work to advance policy-relevant research and communicate it with impact: http://spr.ly/6180QZ7yg

Today we announced that Jen Norton of Takeda will serve as Chair of NPC’s Board of Directors for 2025. We also announced the Executive Committee for 2025: - Rekha Ramesh, Gilead Sciences (Vice Chair) - Bruce Wilson, AstraZeneca (Treasurer, Audit & Budget Committee Chair) - Christine Marsh, Boehringer Ingelheim (Immediate Past Chair) - Jeremy Allen, Spark Therapeutics, Inc. (Member-At-Large) NPC’s work to inform important health policy discussions through our policy-relevant research will benefit from the expertise and leadership of our incoming board. Read more here: https://lnkd.in/gCbQvVkE

Today in NPC This Week: 340B reform, FDA accelerated approvals, and more. Want to get NPC This Week in your inbox? Subscribe here: https://lnkd.in/ekY9Dxzr

Today in NPC This Week: Measures to increase gene therapy access, new state 340B data, proposed CMS changes, and more. Want to get NPC This Week in your inbox? Subscribe here: https://lnkd.in/ekY9Dxzr

Thanks to Shawn Gremminger for hosting a terrific panel with Sarah Emond, Caroline Pearson, and Nilay Shah on "Unlocking Value: Building Trusted Tools to Assess High-Value Care." Employers have an important role in making the healthcare ecosystem work better for patients. We all agree that we need to help employers find value in medicines, not just rebates. Current value assessment frameworks don’t incorporate everything employers need to do so. NPC looks forward to continuing to share our research on this important topic with the National Alliance of Healthcare Purchaser Coalitions and its members. #NatAllForum #employers #employeehealth

📝 Looking for a comprehensive analysis of gene therapy access challenges and policy solutions? NPC's newest publication provides a fresh perspective on building a sustainable future for these innovative treatments.   Our paper in the Becaris Publishing Limited Journal of Comparative Effectiveness Research (JCER) outlines challenges facing the gene therapy market and how our understanding of these challenges can promote more comprehensive and informed policy solutions to improve access to current — and future — gene therapy treatments. ➡️ Read more here! https://lnkd.in/ekUgbJq4 National Pharmaceutical Council #genetherapy #healthpolicy #innovation #NewPublication #research